Niedermeier Andrea, Wörl Petra, Barth Sandra, Schuler Gerold, Hertl Michael
Universitätsklinikum Giessen und Marburg, Klinik für Dermatologie und Allergologie, Standort Marburg.
Eur J Dermatol. 2006 May-Jun;16(3):266-70.
Rituximab is a monoclonal antibody directed against the CD20 antigen of B cells, which has been developed for the treatment of lymphomas and has been successfully used in the treatment of recalcitrant pemphigus vulgaris. Here, we report on a 26-year-old patient with an 18 month history of pemphigus vulgaris of the oral mucosa where treatment with rituximab led to a delayed but sustained therapeutic response. This case is of interest since most of the previous reports have described a more rapid clinical improvement of refractory pemphigus by rituximab treatment. The delayed clinical response to rituximab of the present case may be explained by the persistence of long-lived plasma cells that continued to produce pathogenic autoantibodies against desmoglein 3.
利妥昔单抗是一种针对B细胞CD20抗原的单克隆抗体，已被开发用于治疗淋巴瘤，并已成功用于治疗顽固性寻常型天疱疮。在此，我们报告一名26岁患有口腔黏膜寻常型天疱疮18个月病史的患者，利妥昔单抗治疗导致了延迟但持续的治疗反应。该病例值得关注，因为之前的大多数报告描述了利妥昔单抗治疗难治性天疱疮能使临床更快改善。本病例对利妥昔单抗的延迟临床反应可能是由于长寿浆细胞持续存在，这些细胞继续产生针对桥粒芯糖蛋白3的致病性自身抗体。
